# BP2202

Source: https://onco.cc/drugs/bp2202/  
OnCo record `bp2202` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

BP2202 is an experimental iPS cell-derived CAR-iNKT cell therapy from BrightPath Biotherapeutics, in phase 1 trials for relapsed or refractory multiple myeloma.

## Summary

BP2202 is an iPS cell-derived CAR-iNKT cell therapy (allogeneic) from BrightPath Biotherapeutics. An off-the-shelf allogeneic CAR therapy using NKT cells regenerated from iPS cells, targeting BCMA on myeloma cells. Its furthest stage is phase 1, for relapsed or refractory multiple myeloma. ClinicalTrials.gov registers it in one study linked below. US phase 1 NCT07667868 not yet recruiting (registry, 3 Nov 2026). FDA orphan drug designation July 2025 per company page. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: BP2202
- Modality: iPS cell-derived CAR-iNKT cell therapy (allogeneic)
- Mechanism: An off-the-shelf allogeneic CAR therapy using NKT cells regenerated from iPS cells, targeting BCMA on myeloma cells.

## Sources

- BrightPath Biotherapeutics: brightpathbio.com: https://www.brightpathbio.com/pipeline/bp2202.html
- BrightPath Biotherapeutics: brightpathbio.com: https://www.brightpathbio.com/pipeline/bp2202.html
- BrightPath Biotherapeutics: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT07667868
- ClinicalTrials.gov: trials of BP2202: https://clinicaltrials.gov/search?intr=BP2202

## Connected records

- cancers: [Relapsed or refractory multiple myeloma](https://onco.cc/cancers/myeloma-relapsed-refractory/)
- targets: [BCMA](https://onco.cc/targets/bcma/)
- companies: [BrightPath Biotherapeutics](https://onco.cc/companies/brightpath-biotherapeutics/)
- trials: [A Phase I, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed/Refractory Multiple Myeloma](https://onco.cc/trials/nct07667868/)

---
JSON: https://onco.cc/api/v1/entities/bp2202.json